Covaxin phase 2 trials show vaccine safe, induces immune response
The Hindu
India's first indigenous vaccine against COVID-19, Covaxin, is safe and generates immune response without any serious side effects, according to the interim results of the phase 2 trials published in The Lancet Infectious Diseases journal.
The authors of the study noted that the phase 2 results did not asses the efficacy of the vaccine codenamed BBV152.
More Related News